Social cognition is an important outcome in schizophrenia research. Unfortunately, there has been a lack of consensus regarding which measures of social cognition best capture this domain of functioning. The Social Cognition Psychometric Evaluation (SCOPE) study was developed to address the need for a battery of measures that have sound psychometric properties and can be implemented in clinical trials for individuals with chronic schizophrenia. The current study expands upon the SCOPE study by examining the psychometric properties of the eight candidate measures administered to individuals early in the course of psychosis. Thirty-eight stable outpatients with first episode psychosis and thirty-nine healthy controls completed the battery at baseline and one-month follow-up assessments. The SCOPE battery was evaluated on a collection of psychometric properties, including: (1) Reliability -including test-retest and internal consistency, (2) Between group differences, (3) Utility as a repeated measure, (4) Relationship to social and occupational functioning, (5) Incremental validity -variance in functioning beyond neurocognition, and (6) Feasibility -including practicality of administration and tolerability. Social cognition accounted for substantially more variance in functional outcome than neurocognition. Only one measure, the Hinting task, displayed adequate psychometric properties to be recommended for use in clinical research with first episode psychosis. The remaining candidate measures would require modifications before implementation or cannot be recommended for use in clinical research with first episode psychosis.
Introduction
Social cognition, defined as the mental processes underlying people's capacity to perceive, process and comprehend social information, is related to quality of life, daily living skills and occupational functioning in schizophrenia (Frith, 2008; Green et al., 2012 , Kunda, 1999 Mancuso et al., 2011) . Social cognition accounts for additional variance in functioning than various cognitive factors (Brϋne et al., 2007) , and mediates the relationship between neurocognition and functioning in psychosis (Fett et al., 2011; Schmidt et al., 2011) . Based on its relation to functional outcome, social cognition in schizophrenia has garnered considerable research interest over the past few decades and is increasingly considered a viable target for treatment (Couture et al., 2006; Fett et al., 2011; Green and Leitman, 2008; Penn et al., 1997) .
Despite burgeoning interest in studying social cognition, studies investigating this construct vary greatly in the tasks employed, many of which may lack a strong empirical foundation and involve unknown or questionable psychometric properties (Couture and Penn, 2012; Fett et al., 2011; Savla et al., 2013; Thompson et al., 2011) . The absence of a validated battery of social cognitive measures is problematic as inadequate and inconsistent measurement can jeopardize the validity, reproducibility, and comparability of findings, and may lead to effective treatments being discarded or ineffective treatments pursued (Drost, 2011) .
To address this need, an ongoing NIMH project called the Social Cognition Psychometric Evaluation (SCOPE) study was initiated (Pinkham et al., 2014; Pinkham et al., 2015) . SCOPE is a multiphase project that involves identifying the currently accepted domains of social cognition, selecting the best available measures to assess these domains, and administering tasks to a large sample of stable outpatients with schizophrenia and demographically-matched controls.
Findings from the initial validation study suggested the Bell-Lysaker Emotion Recognition Task (BLERT; Bell et al., 1997) , Penn Emotion Recognition Task (ER-40; Kohler et al., 2003) , Reading the Mind in the Eyes Test (Eyes; Baron-Cohen et al., 2001) , The Awareness of Social Inferences Test (TASIT; McDonald et al., 2003) , and Hinting Task (Hinting; Corcoran et al., 1995) , displayed acceptable reliability and validity for implementation in clinical research. Remaining measures, including: Ambiguous Intentions Hostility Questionnaire (AIHQ; Combs et al., 2007) , Relationships Across Domains (RAD; Sergi et al., 2009) , and Trustworthiness Task (Trust; Adolphs et al., 1998) , demonstrated weaker characteristics and were deemed inadequate for use in clinical trials targeting social cognition (Pinkham et al., 2015) , although subsequent findings support continued development and use of the AIHQ Blame Score (Buck et al., 2017, in press ).
Importantly, SCOPE included a predominantly middle-aged, chronic sample typical of many treatment studies. There is some debate as to whether first episode psychosis (FEP) and chronic schizophrenia patients should exhibit the same types and degree of social cognitive impairment (Savla et al., 2013; Thompson et al., 2011; Ventura et al., 2015) . Some research suggests attenuated or unremarkable deficits earlier in the course of illness (An et al., 2010; Bora and Pantelis, 2013; Romero-Ferreiro et al., 2016; Sprong et al., 2007) , though findings are mixed (Barkl et al., 2014; Green et al., 2012; Horan et al., 2012; Zaytseva et al., 2013) . FEP samples may also be more heterogeneous than many chronic schizophrenia samples (Birchwood et al., 1998) , and differences in social cognition across phase of illness may stem from variations in clinical stability (Bora and Pantelis, 2013; Green et al., 2012) and age-related changes in neurocognitive abilities (Hartshorne and Germine, 2015) . Consequently, the results of SCOPE may not accurately represent younger individuals with FEP.
The purpose of the current study was to extend Pinkham et al.'s (2015) psychometric investigation of the SCOPE battery with a younger FEP sample. Paralleling SCOPE, we report on: (1) Reliability: test-retest, internal consistency, (2) Between-group differences, (3) Utility as a repeated measure, (4) Relationship to social/occupational functioning, (5) Incremental validity: variance in functioning beyond neurocognition, and (6) Feasibility: practicality of administration, tolerability.
Method

Participants
The study took place at the University of North Carolina at Chapel Hill. FEP patients were primarily recruited from the Outreach and Support Intervention Services (OASIS) clinic in Carrboro, NC. Patients required a diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, or psychosis NOS, confirmed by the Structured Clinical Interview for DSM-IV Axis-I Disorders, Patient Edition (SCID-P; First et al., 2002) . OASIS clinicians and/or a trained research assistant at UNC-CH conducted all diagnostic interviews.
Participants were excluded if diagnosed with psychosis for greater than five years, or had been hospitalized within the last two-months. Deterioration is most common before illness onset and during the first few years of psychosis (Birchwood et al., 1998) . Furthermore, evidence indicates a subsequent illness "plateau," during which a level of relative stability is established 2-5 years after illness onset (Srihari et al., 2012) . Thus, a cut-off of five years for illness duration was used. Participants were required to be on a stable medication regimen for a minimum of the two-month hospitalization-free period, though they were not excluded if psychiatrically stable while not receiving antipsychotics.
Control participants were recruited through community flyers and online advertisements. Controls were selected for similarities in age/ gender to outpatient participants. Controls were precluded from participation for meeting criteria for any Axis I/II disorder according to the DSM-IV, or if they had a first-degree family member with a history of psychosis.
All participants were considered ineligible based on: 1) presence/ history of mental retardation, 2) presence/history of brain injury and/ or neurological disorder (e.g., seizures, multiple sclerosis), 3) sensory limitation that would interfere with assessment (e.g., blindness/deafness), and/or 4) evidence of non-nicotine substance dependence in the past six-months, with substance use not being exclusionary. Evidence of substance dependence was collected from patients' healthcare providers, via chart review, and/or through substance use disorder modules from the SCID (DSM-IV; First et al., 2002 Corcoran et al., 1995) ; one measure of social perception-Relationships Across Domains, abbreviated (RAD; Sergi et al., 2009 ); and one novel task that does not fit neatly under the four aforementioned domains-Trustworthiness Task (Trust; Adolphs et al., 1998) .
Neurocognition
Neurocognition was measured using a subset of The MATRICS Consensus Cognitive Battery (MCCB): Trail-Making Test-Part A, BACSSymbol Coding, Category Fluency-Animal Naming, Letter-Number Span, and Hopkins Verbal Learning Test-Revised (Nuechterlein et al., 2008) . Consistent with SCOPE, subtests were selected according to correlations with composite scores of neurocognitive performance (Keefe et al., 2006; Pinkham et al., 2015) . Composite scores were calculated using the standardized mean of corrected t-scores for each subtest (See Appendix A). The Wide Range Achievement Test (WRAT-3) reading-subscale provided an estimate of IQ (Weickert et al., 2000) .
Social and occupational functioning
Social skills were assessed with The Social Skills Performance Assessment (SSPA; Patterson et al., 2001 ). Participant and experimenter acted out two social situations: meeting a new neighbor and persuading a landlord to fix a bathroom leak. Scenes were audio-recorded and rated by a blind-to-diagnosis, expert coder involved in all previous ratings for SCOPE.
Community and daily living skills were assessed using The UCSD Performance-Based Skills Assessment-Brief (UPSA-B; Mausbach et al., 2007) , a performance-based measure of functional capacity, and The Specific Level of Functioning Scale, Self-Report (SLOF; Schneider and Struening, 1983) .
Symptomatology
Symptom severity was measured using The Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) .
Feasibility
Practicality was operationalized as administration time. To assess tolerability, participants rated candidate measures on a Likert-scale from 1-very unpleasant to 7-very pleasant.
Procedure
Participants completed two assessments: baseline and a retest assessment scheduled to occur approximately 4 weeks later. With the project approved by the UNC-CH Institutional Review Board, participants provided signed informed consent and completed social cognitive, neurocognitive, and functional outcome measures at baseline. Task block order and the order of individual tasks within the social cognitive battery were counterbalanced. A rater trained using the same procedures employed in SCOPE conducted diagnostic and symptomatic interviews. Symptoms were reassessed in patients at retest. With the exception of TASIT, for which an alternative form was available, identical social cognitive tasks were administered at retest, in a different counterbalanced order. In accord with the original SCOPE protocol, Version-A was administered at baseline, Version-B at retest.
Statistical analyses
Data analyses were performed using the Statistical Package for the Social Sciences (SPSS, version 23). Statistical significance was defined as p b 0.05. We followed the psychometric validation process employed by the initial validation study (Pinkham et al., 2015) . See Appendix A for details.
Decision-making process regarding SCOPE battery for FEP
To determine the suitability of the SCOPE battery for FEP, we emphasized test-retest reliability, relationship to functional outcome, and ability to distinguish patient and control performance. Acceptable at Present signifies the measure displayed acceptable reliability and validity in the current study, and would not require modifications before use. Acceptable with Concerns indicates specific attributes of the task were concerning and warrant further investigation before implementation. Currently Unacceptable signifies a task displayed weak psychometrics overall and was not recommended.
Results
Participants
Thirty-eight patients and 39 controls completed the baseline assessment. Thirty-five patients and 36 controls returned to complete visit two. Average time between administrations was comparable for both groups (M FEP = 33.08 days, SD = 5.65; M HC = 31.61 days, SD = 4.81; t(70) = −1.190, P = 0.238). Groups did not differ in regard to gender, race, ethnicity, age, or estimated IQ (see Table 1 ). Patients completed significantly fewer years of education than controls, whereas patients' parents completed significantly more years of education than the control sample. Patients reported relatively low levels of symptoms at baseline.
There were significant reductions in positive symptoms from baseline to retest (t(37) = 3.137, P = 0.003, dz = 0.55, r = 0.379). Negative and general symptoms also decreased, though reductions were nonsignificant (negative: t(37) = 1.494, P = 0.144, dz = 0.20, r = 0.338; general: t(37) = 1.959, P = 0.058, dz = 0.26, r = 0.376)( Table 1) .
Psychometric properties 3.2.1. Test-retest reliability
Hinting, RAD, and AIHQ (BS) demonstrated acceptable levels of testretest reliability (Pearson's r values ≥ 0.6) for patients. BLERT, ER-40, Eyes, RAD, and two AIHQ subscales (AB/BS) showed adequate values among controls (Table 2) .
Internal consistency
For patients, few candidate measures approached/exceeded acceptable Cronbach's alpha values (α ≥ 0.8). Exceptions included Trust (0.943), TASIT (0.795) and AIHQ-BS (0.857). Internal consistency was generally lower for controls. Excluding Trust (0.821), values for all tasks administered to controls fell below target standards (Table 2) . Note: Patients reported relatively low levels of symptoms at visit 1, and there were moderate reductions in positive symptoms at visit 2 (t(37) = 3.137, P = 0.003, d z = 0.55). ⁎ p b 0.05. 3.2.3. Group differences Significant group differences were observed only for ER40, Hinting, and TASIT (Table 3 ). The magnitude of between-group differences spanned the moderate-to-large range.
Utility as a repeated measure
For patients, three of eight measures demonstrated statistically significant differences between assessments (Table 4) . Patient performance on ER-40 and Hinting improved, whereas TASIT performance worsened from baseline to retest. Effect sizes were moderate (Cohen's d z range: 0.414-0.642). Compared to the initial psychometric evaluation (Pinkham et al., 2015) , floor/ceiling effects were less evident for this sample. A maximum of two patients (b6%) received perfect or chance-level scores on any measure.
Alternatively, controls performed significantly better on BLERT, ER-40, RAD, and AIHQ-BS at retest. Similar to patients, control performance across versions of the TASIT worsened significantly from baseline to retest. Practice effects varied, with effect sizes in the small-to-medium range (Cohen's d z range: 0.212-0.732). Only one control scored at/ below chance levels on any task (Eyes) during either visit.
With the exception of the second administration of BLERT and first administration of Hinting, b8% of controls scored at ceiling for any candidate measure. Five (12.8%) received perfect scores on BLERT (visit 2), whereas four (10.3%) scored at ceiling on Hinting (visit 1).
Relationship to functional outcome
Correlations between social cognitive and neurocognitive tasks, and functional outcome measures for FEP are provided in Table 5 . With the exception of BLERT, Trust, and AIHQ-AB, most measures demonstrated significant relationships with one or more outcome measures. Significant associations were in the expected direction, and of medium magnitude (range: r = 0.344-0.473).
Incremental validity
Social cognition explained additional variance in functional outcome above and beyond neurocognition. Simple linear regression analyses indicated neurocognition, when entered as a single predictor variable, accounted for 22% of variance in UPSA-B total scores (adjusted R 2 = 0.218, F(1,36) = 11.33, P b 0.01) and 12% of variance in SSPA ratings (adjusted R 2 = 0.123, F(1,35) = 6.039, P b 0.05), but was not a significant predictor of SLOF self-report values (adjusted R 2 = − 0.012, F(1,36) = 0.550, P N 0.05)( Table 6 ). Sequential regression analyses revealed social cognition, entered after neurocognition as a second block, accounted for an additional 20% of variance in community living skills (UPSA-B; R 2 change = 0.199, P b 0.05), 19% of variance in social skills (SSPA; R 2 change = 0.193, P b 0.05), and 21% of variance in realworld functioning (SLOF-SR; R 2 change = 0.214, P b 0.01)( Table 6 ).
Practicality and tolerability
Excluding BLERT administration time (t(75) = 5.78, P = 0.019, d = 0.499) and TASIT enjoyability ratings (t(74) = 5.06, P = 0.027, d = −0.379), practicality and tolerability did not differ significantly between patients and controls (Supplementary Table 1 ). Most measures required b8 min to complete. Participants rated all tasks as relatively pleasant (range: M = 4.29-5.62).
Recommendations
Regarding suitability for FEP, Hinting was the sole measure to be considered Acceptable at Present. RAD was categorized as Acceptable with Concerns. Remaining candidate measures (AIHQ, BLERT, ER40, Eyes, TASIT, Trust) were regarded as Currently Unacceptable. A comparison between our recommendations and the outcome of the initial psychometric evaluation has been provided in Supplementary Table 2. A discussion of convergence and divergence between studies is provided below.
Discussion
The current study evaluated the psychometric properties of the SCOPE battery for FEP. Our findings suggest one measure, the Hinting task, was considered Acceptable at Present, or appropriate for use with FEP patients. In addition to displaying adequate test-retest reliability and effectively distinguishing between patients/controls, Hinting also exhibited significant relationships with both performance-based measures of functioning.
The RAD was classified as Acceptable with Concerns and may be cautiously considered for use with FEP. This measure demonstrated adequate test-retest reliability, a significant relationship to functioning, minimal practice effects, and limited floor/ceiling effects. However, this task was one of the longest to administer and was rated the least enjoyable by patients and controls. RAD's failure to distinguish patients from controls also tempers enthusiasm for this measure. Modification efforts to develop a shortened version may prove beneficial.
The remaining candidate measures were deemed Currently Unacceptable for use with FEP and warrant careful consideration if employed in future clinical trials. Though relatively quick and easy to administer, BLERT and Trust displayed the weakest psychometric properties overall, including poor test-retest reliability, failure to differentiate individuals with/without psychosis, and limited relation to functioning. For the ER40 and TASIT, the primary concern was inadequate test-retest reliability. Based on moderate and significant practice effects observed for the TASIT, there was also concern about possible interference or nonequivalence between versions.
Though AIHQ and Eyes demonstrated significant associations with real-world functioning, predominantly low test-retest reliability estimates and inability to distinguish patients from controls precluded these tasks from recommendation. Notably, however, one subscale of the AIHQ, the BS, was strong on all metrics except group differences. Prior research indicates this subscale of the AIHQ demonstrates adequate psychometric properties, including acceptable internal consistency and test-retest reliability estimates; distinguishes patients from controls; displays significant relationships to functional outcome, and exhibits associations with relevant clinical variables in chronic samples (e.g., hostility and suspiciousness) (Buck et al., 2017, in press ). The AIHQ-BS may therefore benefit from further examination and use; however it will be important to determine if it can be used independently of the rest of the measure.
Note that measures were required to demonstrate adequate testretest reliability among patients, distinguish patients from controls, and exhibit significant relationships to functioning in order to be Given the small sample size, we suggest careful consideration of these recommendations and thoughtful interpretation of the present findings.
In particular, our recommendations may not be as applicable to other research goals (e.g., cross-sectional designs). Consistent with Pinkham et al., our data demonstrate that Hinting is a psychometrically valid theory of mind measure that should be considered appropriate for implementation in psychosis research regardless of stage of illness. Importantly, both Pinkham et al. and the present study utilized a more stringent scoring manual. We emphasize the reported psychometric properties as limited to this revised scoring system (available from AEP upon request). Analyses are underway to determine whether the psychometric properties of the task may change if the original scoring criteria are utilized.
Also consistent with the original SCOPE study, our findings substantiate the claim that social cognition accounts for more variance in functional outcome than various cognitive factors. When measures of social cognition were included in the analyses, the explanatory power of neurocognition dropped significantly. These findings corroborate previous research suggesting social cognition mediates the relationship between neurocognition and functioning in psychosis (Fett et al., 2011; Schmidt et al., 2011) . Together, findings from this study provide strong support for the importance of social cognition in FEP.
In contrast, our findings diverge from the initial psychometric evaluation in a number of ways. Although the BLERT displayed some of the strongest properties in SCOPE, it was one of the weakest measures when administered to FEP outpatients. Whereas only two AIHQ subscales (HB/AB) showed inadequate test-retest reliability among patients in SCOPE, Hinting, RAD and one subscale of the AIHQ (BS) were the only measures to reach acceptable levels when administered to FEP. Reliability estimates were generally lower for controls than patients in SCOPE, while the opposite was observed in our sample. In addition, excluding one AIHQ subscale (AB), all social cognitive tasks adequately differentiated between clinical and normative groups in Pinkham et al. Alternatively, significant group differences were observed for fewer than half the battery when administered to a younger sample.
Certain procedural incongruences and sample differences between our study and the original SCOPE study may have contributed to lower test-retest reliability estimates, differential sensitivity to group differences, and limited relationship to functional outcome. Effect sizes indicating meaningful changes in performance between visits suggested clinically relevant practice effects for half the battery when administered to a younger sample (Table 4) . Memory and practice effects have been shown to adversely affect test-retest reliability (Abner et al., 2012; Broglio et al., 2007; Greig et al., 2004) . In fact, post-hoc independent samples t-tests indicated educational attainment and general intelligence for our patient sample were significantly higher than chronic patients in SCOPE (Equal variances assumed, Education: t = −3.55, P b 0.001; IQ: t = −4.56, P b 0.001).
Remarkably, FEP performance was more comparable to controls than patients in SCOPE (Supplementary Table 3 ). Higher levels of general intelligence in the FEP sample may explain the absence of floor effects for the RAD observed in the initial psychometric evaluation. It is also plausible that learning and memory influenced performance at retest and weakened reliability estimates. Implementing dual-baseline assessments, establishing a "learning plateau," and/or employing truly equivalent alternate forms may bolster test-retest reliability of these measures (Beglinger et al., 2003; Beglinger et al., 2005) .
Psychosis onset typically occurs during late adolescence and early adulthood, a period of developmental transition and social/lifestyle changes that may contribute to less stable social cognition early in the course of illness . To assess the possibility that changes in symptom severity between visits may have impacted social cognitive performance, we recalculated test-retest correlations controlling for symptom fluctuations. Values were unchanged, thus indicating it is unlikely symptom variability accounted for lower test-retest reliability estimates. Specific differences between our clinical sample and that of SCOPE may also explain why measures did not reliably differentiate patients and controls, and clarify the limited value of most tasks as independent predictors of functional outcome. Post-hoc analyses revealed our FEP sample outperformed chronic patients on all tasks (Supplementary  Table 3 ). It is plausible that social cognitive deficits are less prominent early in the course of illness and/or the outcome measures used to assess social functioning and daily living skills are inappropriate for younger patients.
Finally, certain limitations must be considered. First, the inclusion of a relatively small sample, especially compared to the original SCOPE study, is a noteworthy limitation of the present study. Additionally, data were collected from a relatively homogenous sample of predominantly white, well-educated males from one of the fastest-growing metropolitan areas in the United States. FEP patients were also recruited from a coordinated specialty care clinic focused on early intervention and recovery, and may qualitatively differ from clinical samples recruited from more traditional community mental health centers. Thus, interpretations of the present findings should be regarded with caution.
In summary, the present study indicates social cognitive assessment needs to be approached differently for individuals early in the course of illness, and investigators should use caution when employing tasks that have been used primarily with chronic samples. This underscores the need for the development of new measures for use with FEP, as well as a better understanding of how social cognition and functioning may differ across stage of illness. In addition to improving the validity, reproducibility, and comparability of research findings, we may use this information to tailor treatment and develop targeted interventions for FEP.
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